engleski

Cerebrospinal fluid and serum soluble glycoprotein 130 (sgp130 levels) in patients with relapsing-remitting multiple sclerosis

Introduction: Glycoprotein 130 is a signal-transducing receptor subunit of the proinflammatory cytokine inteleukin-6, which is implicated in the pathogenesis of multiple sclerosis (MS). Soluble form of gp130 (sgp130) can be found in human serum. The aim of this study was to measure the sgp130 in the cerebrospinal fluid (CSF) and serum from relapsing-remitting MS patients during acute exacerbation of the disease. Patients and methods: We analysed CSF and serum samples of 17 relapsing-remitting MS patients during acute exacerbation of the disease and 15 patients with noninflammatory neurological diseases (NIND). Sgp130 levels were measured using specific enzymeimmuno test (ELISA). One-way ANOVA was applied for statistical analysis of the data. Results: Our preliminary results show that there is no significant difference in the levels of sgp130 in CSF and serum between MS and NIND patients. Conclusion: These preliminary results indicate that sgp130 might not be the marker of the acute MS exacerbation.

gp130; CSF; serum; multiple sclerosis

nije evidentirano